Clinical Trial Update: Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Bimatoprost 0.03% solution with NB-UVB versus its use with a fractional CO2 laser for vitiligo. The study status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• bimatoprost 0.03% solution (bimatoprost)

Snippet

Sponsor: Assiut University | Conditions: Generalized Vitiligo | Phase 4 | Status: UNKNOWN